遠大醫藥(00512.HK)擬認購8470.5萬股Sirtex HoldCo股份及法外貿訂立收益互換協議
格隆匯7月2日丨遠大醫藥(00512.HK)發佈公吿,2021年7月1日,公司全資擁有的附屬公司弘年與法外貿及Sirtex HoldCo 訂立了股權認購協議,據此,弘年同意認購Sirtex HoldCo擬配發的8470.465萬股Sirtex HoldCo股份(代表因認購事項擴大的Sirtex HoldCo的已發行股本的8.00%),代價為1億美元;及法外貿同意認購,及Sirtex HoldCo同意配發4235.233萬股Sirtex HoldCo股份(代表因認購事項擴大的Sirtex HoldCo的已發行股本的4.00%),代價為5000萬美元;及公司與法外貿訂立了收益互換協議,內容為(其中包括)法外貿可向公司轉移法外貿於法外貿認購事項中收購的Sirtex HoldCo股份的所有經濟收益。
Sirtex HoldCo連同Sirtex BidCo是因Sirtex收購事項而由集團及CDH Genetech於2018年成立的特殊目的公司。 Sirtex為一間澳洲註冊的全球性生命科學公司,其目前的主要收入來源是SIR-Spheres產品的銷售,該產品為一款肝癌(晚期)的針對性放射治療方法。Sirtex的SIR-Spheres產品已向全球超過40個國家供應,收入來源主要源自美國。
公吿表示,集團的策略為進一步投資精準介入腫瘤學,並持續發展Sirtex的現有業務並全面利用SIR-Spheres Y-90樹脂微球於中國的巨大潛力。弘年認購事項及收益互換交易將使集團增加於Sirtex的股東權益,而其全球性創新醫藥產品將會進一步強化集團的產品管線。訂立收益互換協議將使公司維持對法外貿於法外貿認購事項中收購的Sirtex HoldCo股份的所有經濟收益但不用付出全數代價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.